GRAIL, Inc. (GRAL) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $51.57: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation.
GRAIL is a commercial-stage healthcare company offering Galleri, an FDA PMA-pending multi-cancer early detection blood test that screens for many cancer types from a single draw. Galleri accounts for substantially all revenue; the NHS-Galleri Trial did not meet its primary... Read more
Sell if holding. Engine safety override at $51.57: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 63. Score 4.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductGalleri10-K Item 1A: 'Sales of Galleri accounted for a substantial majority of our revenue to date and we expect that such sales will continue to account for the substantial majority of our revenue for the foreseeable future'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -277.5%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $51.57: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $48.24. Score 4.2/10, moderate confidence.
Take-profit target: $58.91 (+13.6% upside). Prior stop was $48.24. Stop-loss: $48.24.
Concentration risk — Product: Galleri; Quality below floor (2.9 < 4.0).
GRAIL, Inc. trades at a P/E of N/A (forward -5.9). TrendMatrix value score: 3.8/10. Verdict: Sell.
12 analysts cover GRAL with a consensus score of 4.1/5. Average price target: $68.
What does GRAIL, Inc. do?GRAIL is a commercial-stage healthcare company offering Galleri, an FDA PMA-pending multi-cancer early detection blood...
GRAIL is a commercial-stage healthcare company offering Galleri, an FDA PMA-pending multi-cancer early detection blood test that screens for many cancer types from a single draw. Galleri accounts for substantially all revenue; the NHS-Galleri Trial did not meet its primary endpoint of combined Stage 3 and 4 reduction, creating uncertainty for reimbursement and international expansion.